Modulation Of Bcl11a For Treatment Of Hemoglobinopathies

Abstract

The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.


Claims
CPC Classifications
IPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Feb 6, 2018
  • Application: Jan 4, 2016
    US US 201614987219 A
  • Priority: Jan 4, 2016
    US US 201614987219 A
  • Priority: Jan 17, 2013
    US US 201313743399 A
  • Priority: Sep 14, 2009
    US US 200913063524 A
  • Priority: Sep 14, 2009
    US US 2009/0056770 W
  • Priority: Jul 2, 2009
    US US 22257109 P
  • Priority: Sep 15, 2008
    US US 9701708 P

Download Citation


Sign in to the Lens

Feedback